134 related articles for article (PubMed ID: 21521282)
1. The functional status of incidentally discovered bilateral adrenal lesions.
Androulakis II; Kaltsas GA; Markou A; Tseniklidi E; Kafritsa P; Pappa T; Papanastasiou L; Piaditis GP
Clin Endocrinol (Oxf); 2011 Jul; 75(1):44-9. PubMed ID: 21521282
[TBL] [Abstract][Full Text] [Related]
2. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
Tsagarakis S; Roboti C; Kokkoris P; Vasiliou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 Aug; 49(2):165-71. PubMed ID: 9828902
[TBL] [Abstract][Full Text] [Related]
3. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome.
Tsagarakis S; Kokkoris P; Roboti C; Malagari C; Kaskarelis J; Vlassopoulou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 May; 48(5):627-33. PubMed ID: 9666875
[TBL] [Abstract][Full Text] [Related]
4. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion.
Androulakis II; Kaltsas GA; Kollias GE; Markou AC; Gouli AK; Thomas DA; Alexandraki KI; Papamichael CM; Hadjidakis DJ; Piaditis GP
J Clin Endocrinol Metab; 2014 Aug; 99(8):2754-62. PubMed ID: 24712565
[TBL] [Abstract][Full Text] [Related]
5. Pattern of adrenal hormonal secretion in patients with adrenal adenomas: the relevance of aldosterone in arterial hypertension.
Pappa T; Papanastasiou L; Kaltsas G; Markou A; Tsounas P; Androulakis I; Tsiavos V; Zografos G; Vamvakidis K; Samara C; Piaditis G
J Clin Endocrinol Metab; 2012 Apr; 97(4):E537-45. PubMed ID: 22319028
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas.
Perogamvros I; Vassiliadi DA; Karapanou O; Botoula E; Tzanela M; Tsagarakis S
Eur J Endocrinol; 2015 Dec; 173(6):719-25. PubMed ID: 26330465
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.
Tzanela M; Zianni D; Stylianidou Ch; Karavitaki N; Tsagarakis S; Thalassinos NC
Clin Endocrinol (Oxf); 2005 May; 62(5):597-602. PubMed ID: 15853831
[TBL] [Abstract][Full Text] [Related]
8. Cortisol secretion from adrenal adenomas discovered as incidentalomas is responsive to ACTH.
Olsen H; Olofsson L; Mjöman M
Clin Endocrinol (Oxf); 2014 Mar; 80(3):335-41. PubMed ID: 23865937
[TBL] [Abstract][Full Text] [Related]
9. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas.
Valli N; Catargi B; Ronci N; Vergnot V; Leccia F; Ferriere JM; Chene G; Grenier N; Laurent F; Tabarin A
Eur J Endocrinol; 2001 Apr; 144(4):401-8. PubMed ID: 11275951
[TBL] [Abstract][Full Text] [Related]
10. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study.
Reznik Y; Lefebvre H; Rohmer V; Charbonnel B; Tabarin A; Rodien P; Lecomte P; Bardet S; Coffin C; Mahoudeau J;
Clin Endocrinol (Oxf); 2004 Sep; 61(3):311-9. PubMed ID: 15355446
[TBL] [Abstract][Full Text] [Related]
11. Adrenocortical tumors: prevalence of impaired glucose tolerance and of "Paradoxical Rise" of cortisol during an oral glucose tolerance test.
Vierhapper H; Heinze G; Gessl A; Exner M
Exp Clin Endocrinol Diabetes; 2003 Oct; 111(7):415-20. PubMed ID: 14614648
[TBL] [Abstract][Full Text] [Related]
12. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up.
Papanastasiou L; Alexandraki KI; Androulakis II; Fountoulakis S; Kounadi T; Markou A; Tsiavos V; Samara C; Papaioannou TG; Piaditis G; Kaltsas G
Clin Endocrinol (Oxf); 2017 Apr; 86(4):488-498. PubMed ID: 27992961
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone excess may inhibit insulin secretion: A comparative study on glucose metabolism pre- and post-adrenalectomy in patients with primary aldosteronism.
Tsurutani Y; Sugisawa C; Ishida A; Inoue K; Saito J; Omura M; Nagasaka S; Nishikawa T
Endocr J; 2017 Mar; 64(3):339-346. PubMed ID: 28111382
[TBL] [Abstract][Full Text] [Related]
14. A new less-invasive and more informative low-dose ACTH test: salivary steroids in response to intramuscular corticotrophin.
Contreras LN; Arregger AL; Persi GG; Gonzalez NS; Cardoso EM
Clin Endocrinol (Oxf); 2004 Dec; 61(6):675-82. PubMed ID: 15579180
[TBL] [Abstract][Full Text] [Related]
15. Plasma and salivary 6beta-hydroxycortisol measurements for assessing adrenocortical activity in patients with adrenocortical adenomas.
Varga I; Jakab C; Szücs N; Patócs A; Tóth M; Kiss R; Gláz E; Rácz K
Horm Metab Res; 2003 Jul; 35(7):421-6. PubMed ID: 12931273
[TBL] [Abstract][Full Text] [Related]
16. Enhanced performance of a modified diagnostic test of primary aldosteronism in patients with adrenal adenomas.
Markou A; Kaltsas GA; Papanastasiou L; Gravvanis C; Voulgaris N; Kanti G; Zografos GN; Chrousos GP; Piaditis G
Eur J Endocrinol; 2022 Jan; 186(2):265-273. PubMed ID: 34882580
[TBL] [Abstract][Full Text] [Related]
17. Steroidogenesis in patients with adrenal incidentalomas: Extended steroid profile measured by liquid chromatography-mass spectrometry after ACTH stimulation and dexamethasone suppression.
Huayllas MKP; Smith LM; Gallagher JC; Netzel BC; Singh RJ; Kater CE
Clin Endocrinol (Oxf); 2021 Jul; 95(1):29-40. PubMed ID: 33598999
[TBL] [Abstract][Full Text] [Related]
18. Basal and ACTH-stimulated cortisol and aldosterone release from adrenocortical adenomas in vitro.
Gröndal S; Grimelius L; Thorén M; Hamberger B
Eur J Surg; 1991 Mar; 157(3):179-83. PubMed ID: 1678626
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in 125 individuals with adrenal incidentalomas from a single centre. a retrospective assessment of the 1 mg overnight and low dose dexamethasone suppression tests.
Theodoraki A; Khoo B; Hamda A; Schwappach A; Perera S; Vanderpump MP; Bouloux PM
Horm Metab Res; 2011 Dec; 43(13):962-9. PubMed ID: 22048862
[TBL] [Abstract][Full Text] [Related]
20. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
Falcetta P; Orsolini F; Benelli E; Agretti P; Vitti P; Di Cosmo C; Tonacchera M
Endocrine; 2021 Jan; 71(1):178-188. PubMed ID: 32915435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
